A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants
Status:
COMPLETED
Trial end date:
2024-12-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector, an injection under the skin, compared to mirikizumab (reference) solution given via autoinjector.
Screening is required within 35 days prior to enrollment. For each participant, the total duration for of the clinical trial will be about 15 weeks, including screening.